Open AccessAssessment of topoisomerase II-alpha gene status by dual color chromogenic in situ hybridization in a set of Iraqi patients with invasive breast carcinoma
Author(s) -
Rasha Abd Alraouf Neama,
Manal Habib,
Sahira A. Ali,
Ali Hussein Al-Khafaji,
Mohammed F Alqanbar
Publication year - 2017
Publication title -
indian journal of pathology and microbiology/indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/ijpm.ijpm_62_16
Subject(s) - chromogenic in situ hybridization , cish , breast cancer , gene duplication , breast carcinoma , immunohistochemistry , biology , cancer research , fluorescence in situ hybridization , cancer , estrogen receptor , gene , microbiology and biotechnology , in situ hybridization , medicine , gene expression , chromosome , genetics
The human epidermal growth factor receptor 2(HER2) proto-oncogene is overexpressed or amplified in approximately 15%-25% of invasive breast cancers. Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. Hence, the determination of genetic alteration (amplification or deletion) of both genes is considered as an important predictive factor that determines the response of breast cancer patients to treatment. The aims of this study are to determinate TOP2A status gene amplification in a set of Iraqi patients with breast cancer that have had an equivocal (2+) and positive HER2/neu by immunohistochemistry (IHC) and to compare the results with estrogen receptor (ER) and progesterone receptor (PR) and HER2/neu status.